Tissue engineered stents created from chondrocytes.
OBJECTIVE
Trauma, operations or instrumentation of the urethra or ureter may lead to stricture disease. The use of a natural urethral stent made of autologous tissue would be advantageous due to its biocompatibility. In this study we investigated the feasibility of engineering cartilage stents in vitro and in vivo.


METHODS
We fabricated 40 cylinders 10 mm. long with an inner and outer diameter of 5 and 9 mm., respectively, from polyglycolic acid mesh coated with 50:50 polylactic-co-glycolic acid. Chondrocytes isolated from bovine shoulders were seeded onto the tubular polymer scaffolds at a seeding density of 60 x 106 cells per ml. Scanning electron microscopy was performed to determine the even distribution of chondrocytes throughout the polymer scaffolds. We implanted 20 cylinders under the skin of nude mice and 20 were cultured in stirred bio-reactors. Cytological characteristics, collagen content and mechanical durability were evaluated 4 and 10 weeks after cell seeding.


RESULTS
Gross examination of the engineered stents showed the solid, glistening appearance of cartilaginous tissue. Cytological analyses with hematoxylin and eosin, trichrome, alcian blue and safranin O confirmed cartilage, and the deposition of collagen and glycosaminoglycan in each group. Increased deposition of collagen and glycosaminoglycan was observed in the stents created in vivo. Biomechanical testing demonstrated that the cartilaginous cylinders in each group were readily elastic and withstood high degrees of pressure.


CONCLUSIONS
This study demonstrates the feasibility of creating cartilaginous stents in vitro and in vivo using chondrocyte seeded polymer matrices. This technology may be useful clinically for stricture disease in the genitourinary tract.
Amiel
G E
GE
Laboratory for Tissue Engineering and Cellular Therapeutics, Department of Urology, Children's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Yoo
J J
JJ
Kim
B S
BS
Atala
A
A
D000818:Animals; D001672:Biocompatible Materials; D001698:Biomedical Engineering; D019149:Bioreactors; D002478:Cells, Cultured; D019902:Chondrocytes; D005240:Feasibility Studies; D051379:Mice; D008819:Mice, Nude; D011100:Polyglycolic Acid; D015607:Stents; D014525:Urethral Stricture / Q000628:therapy
D001672:Biocompatible Materials; D011100:Polyglycolic Acid